Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

DT-168

Other · developed by Design Therapeutics

Phase 2 Most advanced trial
DSGN Developer
1 Registered trials

What is DT-168?

DT-168 is studied in Fuchs endothelial corneal dystrophy, a disease of the corneal endothelium.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Ophthalmology
Developer
Design Therapeutics, Inc. (DSGN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07024693 Phase 2 Fuchs Endothelial Corneal Dystrophy Recruiting DSGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

FuchsFuchs Endothelial Corneal Dystrophy

More from Design Therapeutics

DT-216 Phase 1 DT-216P2 Phase 1/2

Follow DSGN, the company behind DT-168

See DSGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

DSGN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.